Literature DB >> 11562535

Definition of neutralizing sites on African horse sickness virus serotype 4 VP2 at the level of peptides.

Jorge L Martínez-Torrecuadrada1, Jan P M Langeveld2, Rob H Meloen2, J Ignacio Casal1.   

Abstract

The antigenic structure of African horse sickness virus (AHSV) serotype 4 capsid protein VP2 has been determined at the peptide level by PEPSCAN analysis in combination with a large collection of polyclonal antisera and monoclonal antibodies. VP2, the determinant for the virus serotype and an important target in virus neutralization, was found to contain 15 antigenic sites. A major antigenic region containing 12 of the 15 sites was identified in the region between residues 223 and 400. A second domain between residues 568 and 681 contained the three remaining sites. These sites were used for the synthesis of peptides, which were later tested in rabbits. Of the 15 synthetic peptides, three were able to induce neutralizing antibodies for AHSV-4, defining two neutralizing epitopes, 'a' and 'b', between residues 321 and 339, and 377 and 400, respectively. A combination of peptides representing both sites induced a more effective neutralizing response. Still, the relatively low neutralization titres make the possibility of producing a synthetic vaccine for AHSV unlikely. The complex protein-protein interaction of the outer shell of the viral capsid would probably require the presence of either synthetic peptides in the correct conformation or peptide segments from the different proteins VP2, VP5 and VP7.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11562535     DOI: 10.1099/0022-1317-82-10-2415

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  6 in total

1.  Structural Protein VP2 of African Horse Sickness Virus Is Not Essential for Virus Replication In Vitro.

Authors:  René G P van Gennip; Sandra G P van de Water; Christiaan A Potgieter; Piet A van Rijn
Journal:  J Virol       Date:  2017-01-31       Impact factor: 5.103

2.  Immunogenicity of recombinant VP2 proteins of all nine serotypes of African horse sickness virus.

Authors:  Yuta Kanai; Piet A van Rijn; Mieke Maris-Veldhuis; Yuki Kaname; T N Athmaram; Polly Roy
Journal:  Vaccine       Date:  2014-07-18       Impact factor: 3.641

3.  B-cell epitopes of African horse sickness virus serotype 4 recognised by immune horse sera.

Authors:  Evans M Mathebula; Frederika E Faber; Wouter Van Wyngaardt; Antoinette Van Schalkwyk; Alri Pretorius; Jeanni Fehrsen
Journal:  Onderstepoort J Vet Res       Date:  2017-02-24       Impact factor: 1.792

Review 4.  African Horse Sickness: A Review of Current Understanding and Vaccine Development.

Authors:  Susan J Dennis; Ann E Meyers; Inga I Hitzeroth; Edward P Rybicki
Journal:  Viruses       Date:  2019-09-11       Impact factor: 5.048

5.  Antiserum from mice vaccinated with modified vaccinia Ankara virus expressing African horse sickness virus (AHSV) VP2 provides protection when it is administered 48h before, or 48h after challenge.

Authors:  Eva Calvo-Pinilla; Francisco de la Poza; Simon Gubbins; Peter Paul Clement Mertens; Javier Ortego; Javier Castillo-Olivares
Journal:  Antiviral Res       Date:  2015-01-30       Impact factor: 5.970

6.  African Horse Sickness Virus Serotype 1 on Horse Farm, Thailand, 2020.

Authors:  Napawan Bunpapong; Kamonpan Charoenkul; Chanakarn Nasamran; Ekkapat Chamsai; Kitikhun Udom; Supanat Boonyapisitsopa; Rachod Tantilertcharoen; Sawang Kesdangsakonwut; Navapon Techakriengkrai; Sanipa Suradhat; Roongroje Thanawongnuwech; Alongkorn Amonsin
Journal:  Emerg Infect Dis       Date:  2021-08       Impact factor: 6.883

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.